Lacosamide Injection

Efficacy: This product is suitable for the combined treatment of partial seizures in patients with epilepsy aged 4 years and above.
Dosage and Administration: This product should be taken twice a day (usually once in the morning and once in the evening). The recommended starting dose is 50 mg each time, twice a day, and after one week it should be increased to an initial therapeutic dose of 100 mg each time, twice a day. The starting dose of this product can also be a single loading dose of 200 mg, and a maintenance dose of 100 mg each time, twice a day (200 mg/day) is used about 12 hours later. When the doctor determines that it is necessary to quickly achieve a steady-state plasma concentration and efficacy of lacosamide, the patient can be given a loading dose. Considering the possible increase in the incidence of adverse reactions to the central nervous system, the loading dose should be administered under medical supervision. Based on efficacy and tolerability, the maintenance dose can be increased weekly by 50 mg each time; twice a day (100 mg per week) until the maximum recommended daily dose of 400 mg (200 mg each time, twice a day). If lacosamide must be discontinued, it is recommended to discontinue the drug gradually (for example, gradually reduce the daily dose by 200 mg/week). The same drugs produced by different manufacturers may have inconsistent instructions. If you find that the instructions are inconsistent before taking the medicine, please consult a doctor or pharmacist in time.
Adverse reactions:
Abnormalities of the blood and lymphatic system: agranulocytosis. Immune system abnormalities: drugs, hypersensitivity reactions, drug reactions with eosinophilia and systemic symptoms. Mental abnormalities: depression, confusion, insomnia, aggressive behavior, agitation, euphoria, mental abnormalities, suicide attempts, suicidal thoughts, hallucinations. Nervous system abnormalities: dizziness, headache, balance disorder, coordination disorder, memory impairment, cognitive impairment, drowsiness, tremor, nystagmus, hypoesthesia, dysarthria, attention disorder, paresthesia, syncope, convulsions. Eye abnormalities: diplopia, blurred vision. Ear and labyrinth abnormalities: vertigo, tinnitus. Cardiac abnormalities: atrioventricular conduction block, bradycardia, atrial fibrillation, atrial flutter. Digestive system abnormalities: nausea, vomiting, constipation, flatulence, indigestion, dry mouth, diarrhea. Hepatobiliary abnormalities: abnormal liver function tests, elevated liver enzymes (>2xULN). Skin and subcutaneous tissue abnormalities: pruritus, rash, angioedema, urticaria, Stevens-Johnson syndrome, toxic epidermal necrolysis. Musculoskeletal and connective tissue abnormalities: muscle spasms. General discomfort and administration site abnormalities: gait disturbance, weakness, fatigue, irritability, feeling of drunkenness.
Drug contraindications:
Allergic to this product. Prohibited from driving. Use with caution. Use with caution in patients with impaired liver and kidney function. Use with caution in children. Use with caution during pregnancy. Use with caution during lactation.